Fulcrum Therapeutics Inc
NASDAQ:FULC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.97
12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Fulcrum Therapeutics Inc
Wall Street
Price Targets
FULC Price Targets Summary
Fulcrum Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
FULC
is 5.39 USD
with a low forecast of 2.02 USD and a high forecast of 14.7 USD.
FULC Last Price Targets
Fulcrum Therapeutics Inc
The latest public price target was made on Sep 13, 2024 by
Andrew Fein
from
H.C. Wainwright
,
who expects
FULC
stock to
drop by 8%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Andrew Fein
H.C. Wainwright
|
4
USD
Downside 8% |
3 months ago
Sep 13, 2024
|
Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TheFly
|
Gregory Renza
RBC Capital
|
4
USD
Downside 8% |
3 months ago
Sep 12, 2024
|
Fulcrum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
TheFly
|
Tazeen Ahmad
Bank of America Securities
|
2
USD
Downside 54% |
3 months ago
Sep 12, 2024
|
BofA Securities Downgrades Fulcrum Therapeutics (FULC) to Underperform
StreetInsider
|
Dae Gon Ha downgraded Fulcrum Therapeutics
Stifel Nicolaus
|
3
USD
Downside 31% |
3 months ago
Sep 12, 2024
|
Fulcrum Therapeutics downgraded to Hold from Buy at Stifel
TheFly
|
|
Tazeen Ahmad
Bank of America Securities
|
10
USD
Upside 129% |
4 months ago
Sep 9, 2024
|
BofA Securities Upgrades Fulcrum Therapeutics (FULC) to Neutral
StreetInsider
|
|
Gregory Renza
RBC Capital
|
15
USD
Upside 243% |
4 months ago
Sep 3, 2024
|
Fulcrum Therapeutics (FULC) PT Raised to $15 at RBC Capital
StreetInsider
|
|
Kristen Kluska
Cantor Fitzgerald
|
23
USD
Upside 426% |
7 months ago
May 20, 2024
|
Cantor Fitzgerald Starts Fulcrum Therapeutics (FULC) at Overweight
StreetInsider
|
|
Dae Gon Ha
Stifel Nicolaus
|
22
USD
Upside 403% |
7 months ago
May 13, 2024
|
Fulcrum Therapeutics (FULC) PT Raised to $22 at Stifel
StreetInsider
|
Corinne Jenkins
Goldman Sachs
|
15
USD
Upside 243% |
7 months ago
May 13, 2024
|
Goldman Sachs Upgrades Fulcrum Therapeutics (FULC) to Buy
StreetInsider
|
|
Gregory Renza
RBC Capital
|
14
USD
Upside 220% |
9 months ago
Mar 13, 2024
|
RBC Capital Starts Fulcrum Therapeutics (FULC) at Outperform, 'A Rare Disease Pipeline with Its DUX in a Row'
StreetInsider
|
| Price Target | 3 USD |
| Upside/Downside | 31% |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is FULC's stock price target?
Price Target
5.39
USD
According to Wall Street analysts, the average 1-year price target for
FULC
is 5.39 USD
with a low forecast of 2.02 USD and a high forecast of 14.7 USD.
You don't have any saved screeners yet
